Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâs disease psychosis, epilepsy, panic disorder and Parkinsonâs disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâs disease.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-31 EDT			5-day change	1st Jan Change
44.96 ^USD	+0.74%		-.--%	-.--%

2024	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
2024	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI

Capitalization	8.19B 7B 6.53B 6.04B 11.21B 703B 12.56B 78.24B 29.7B 328B 30.72B 30.09B 1,203B	P/E ratio 2022	-13.6x	P/E ratio 2023	-15.9x
Enterprise value	7.5B 6.4B 5.98B 5.53B 10.26B 643B 11.49B 71.6B 27.18B 300B 28.11B 27.53B 1,101B	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	93.64%	Yield 2022 *	-	Yield 2023	-

Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	24-08-04	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	24-08-04	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P TMI Index	24-08-04	CI
Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....	24-08-02
AbbVie Completes Acquisition of Cerevel Therapeutics	24-08-01	MT
AbbVie Completes Acquisition of Cerevel Therapeutics	24-08-01	MT
Cerevel Therapeutics Holdings, Inc. Announces Board Changes	24-08-01	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from NASDAQ Composite Index	24-07-31	CI
AbbVie Inc. completed the acquisition of Cerevel Therapeutics Holdings, Inc. from FMR LLC and others.	24-07-31	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Dynamic Index	24-06-30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Growth Index	24-06-30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Index	24-06-30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Index	24-06-30	CI

Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....	24-08-02
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	24-05-14	MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	24-02-15	MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	23-12-28	MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	23-12-22	MT

Cerevel Therapeutics Holdings, Inc. Stock

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Valuation: Cerevel Therapeutics Holdings, Inc.

Chart: Cerevel Therapeutics Holdings, Inc.

Latest news: Cerevel Therapeutics Holdings, Inc.

Analysts' recommendations: Cerevel Therapeutics Holdings, Inc.

Press Releases: Cerevel Therapeutics Holdings, Inc.

News in other languages: Cerevel Therapeutics Holdings, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cerevel Therapeutics Holdings, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP	06-03	BU
CERE DEADLINE NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE	05-31	NE
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics	05-31	PR
CERE DEADLINE ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE	05-26	NE
CERE DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE	05-24	NE

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Alphabet, Amazon, Lululemon, Intel, Qualcomm....	24-08-02
USA-Les valeurs à suivre à Wall Street (actualisé)	24-02-22
Omzetdaling Abbvie valt mee	24-02-02
Pharma und Gesundheit: weitere Konsolidierung	23-12-13
Farma en gezondheid: consolidatie gaat door	23-12-12

1 year	40.19	44.99
3 years	19.59	44.99
5 years	9	46.16
10 years	9	46.16

Manager	Title	Age	Since
Ronald Renaud CEO	Chief Executive Officer	56	2023-06-11
Scott Reents PSD	President	58	2024-07-31
Susan Altschuller DFI	Director of Finance/CFO	43	2023-05-14

Director	Title	Age	Since
Deborah Baron BRD	Director/Board Member	56	2021-01-19
Scott Reents BRD	Director/Board Member	58	2024-07-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CEREVEL THERAPEUTICS HOLDINGS, INC.	+0.74%	-.--%	+10.77%	+54.50%	8.19B
ARGENX SE	-0.39%	-1.21%	+15.25%	+26.70%	33.25B
WUXI APPTEC CO., LTD.	+0.80%	-0.42%	+90.94%	-36.12%	28.1B
BIONTECH SE	+1.46%	+3.86%	+38.73%	-34.37%	27.49B
INSMED INCORPORATED	-0.84%	-1.52%	+37.24%	+287.66%	18.26B
SUMMIT THERAPEUTICS INC.	+1.68%	+8.44%	+204.50%	+2,153.92%	17.07B
WUXI BIOLOGICS (CAYMAN) INC.	+1.17%	+1.17%	+140.72%	-67.56%	13.32B
AKESO, INC.	-0.18%	+18.21%	+199.32%	+346.84%	12.55B
GENMAB A/S	+4.24%	+3.69%	-22.31%	-44.32%	13.16B
EXELIXIS, INC.	-1.47%	-0.25%	+96.97%	+97.68%	11.87B
Average	+0.48%	+3.17%	+81.21%	+278.49%	18.33B
Weighted average by Cap.	+0.44%	+2.42%	+74.32%	+247.91%

	2022	2023
Net sales	-	-
Net income	-352M -300M -280M -259M -481M -30.16B -539M -3.36B -1.27B -14.07B -1.32B -1.29B -51.61B	-433M -370M -345M -319M -592M -37.13B -664M -4.13B -1.57B -17.32B -1.62B -1.59B -63.55B
Net Debt	-523M -447M -417M -386M -716M -44.89B -802M -5B -1.9B -20.94B -1.96B -1.92B -76.82B	-695M -594M -554M -513M -952M -59.66B -1.07B -6.64B -2.52B -27.83B -2.61B -2.55B -102B